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Abstract
Objectives To test whether bisphosphonate use is related to improved
implant survival after total arthroplasty of the knee or hip.
Design Population based retrospective cohort study.
Setting Primary care data from the United Kingdom.
Participants All patients undergoing primary total arthroplasty of the
knee (n=18 726) or hip (n=23 269) in 1986-2006 within the United
Kingdom’s General Practice Research Database. We excluded patients
with a history of hip fracture before surgery or rheumatoid arthritis, and
individuals younger than 40 years at surgery.
Intervention Bisphosphonate users were classified as patients with at
least six prescriptions of bisphosphonates or at least six months of
prescribed bisphosphonate treatment with more than 80% adherence
before revision surgery.
Outcome measures Revision arthroplasties occurring after surgery,
identified by READ and OXMIS codes. Parametric survival models were
used to determine effects on implant survival with propensity score
adjustment to account for confounding by indication.
Results Of 41 995 patients undergoing primary hip or knee arthroplasty,
we identified 1912 bisphosphonate users, who had a lower rate of
revision at five years than non-users (0.93% (95% confidence interval
0.52% to 1.68%) v 1.96% (1.80% to 2.14%)). Implant survival was
significantly longer in bisphosphonate users than in non-users in
propensity adjusted models (hazard ratio 0.54 (0.29 to 0.99); P=0.047)
and had an almost twofold increase in time to revision after hip or knee
arthroplasty (time ratio 1.96 (1.01 to 3.82)). Assuming 2% failure over
five years, we estimated that the number to treat to avoid one revision
was 107 for oral bisphosphonates.
Conclusions In patients undergoing lower limb arthroplasty,
bisphosphonate use was associated with an almost twofold increase in
implant survival time. These findings require replication and testing in
experimental studies for confirmation.
Introduction
Osteoarthritis is the most common form of arthritis in the
Western world, with total joint arthroplasty being the most
effective therapy for severe osteoarthritis of the lower limb.
1
Osteoarthritis accounted for 97% of 71 527 primary total
arthroplasties of the knee and for 93% of 64 772 primary total
arthroplasties of the hip performed in the United Kingdom in
2009.
2 Furthermore, increases in the numbers of elderly and
obeseindividualshavedrivenupratesofprimaryarthroplasty.
3
Revision surgery has a poorer clinical outcome than primary
joint surgery
4 5 and is more costly.
6 According to the 7th annual
report of the National Joint Registry for England and Wales,
revision rates at five years were 2.9% and 3.6% for total hip
and knee arthroplasties, respectively (using data collected from
2003 to 2009).
2 In 2003, about one in 75 patients needed a
revision of their prosthesis within three years.
7 The most
common cause of revision is loosening, which occurs if the
bone supporting the implant is resorbed.
2 Bone remodelling at
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Research
RESEARCHthe bone-implant interface leads to localised bone lysis, which
may also result in the need for revision.
8
Efforts to identify patients at risk of revision and develop new
treatments to improve implant survival are urgently needed.
Bisphosphonates, through their antiresorptive properties on
osteoclast activity, have potential protective effects on implant
survival.
4 Some randomised clinical trials,
9-12 but not all,
13 have
suggested a potential benefit of bisphosphonate treatment on
implant survival after total arthroplasty of the knee or hip, by
showing improvements in surrogate outcomes such as implant
migration. However, none of the trials had used revision of the
implant as the primary outcome.
Weaimedtotestwhetherbisphosphonateuseisassociatedwith
increased survival of implants in the lower limb after primary
total arthroplasty.
Methods
Study population
We used a cohort of patients from the United Kingdom’s
General Practice Research Database with a medical diagnosis
codeforprimarytotalarthroplastyofthehiporkneefrom1986
totheendof2006.Thedatabasecomprisescomputerisedrecords
of all clinical and referral events in both primary and secondary
care in addition to comprehensive demographic information.
Dataincludemedicationprescriptions,clinicalevents,specialist
referrals, and hospital admissions with their major outcomes in
asampleof6.5millionpatientsfrom433contributingpractices,
chosen to be representative of the wider UK population. The
database, which is managed by the Medicines and Healthcare
Products Regulatory Agency,
14 only includes general practices
that pass quality control. Deletion or encoding of personal and
clinic identifiers ensures the confidentiality of information in
the database. Data are stored using OXMIS (Oxford Medical
Information System (UK)) and READ codes for diseases that
are cross referenced to the International Classification of
Diseases(ICD-9);weusedthesecodestoidentifyprimarytotal
arthroplasty of the knee or hip.
Patients were included in the analysis if aged 40 years or over
at the time of surgery. We excluded individuals with a medical
diagnosis code for rheumatoid arthritis. Since we could not
accurately differentiate patients undergoing arthroplasty for
osteoarthritis from those undergoing arthroplasty for either an
acute hip fracture or a late complication of hip fracture, we
excluded individuals with a history of hip fracture before
primary arthroplasty. Using these criteria, we identified 41 995
eligible participants: 23 269 with hip arthroplasty and 18 726
with knee arthroplasty. To calculate the rate of revision, we
followed up patients for a maximum of 15 years after surgery.
Main outcome
Themainoutcomeofthisstudywasimplantsurvival,calculated
as the time from primary total arthroplasty to revision surgery.
We identified patients undergoing a surgical revision by using
their READ and OXMIS codes (web appendix).
Identification of bisphosphonate users
According to the General Practice Research Database, patients
wereprescribedthefollowingoralbisphosphonates:alendronate,
etidronate, ibandronate, and risedronate. We defined
bisphosphonate users by two criteria. Firstly, we identified
patients who had been prescribed bisphosphonates by their
general practitioner at least six months before revision surgery
for at least six months and who had a high adherence—that is,
a medication possession ratio of more than 80%.
15 The
medicationpossessionratioisdefinedastheproportionofdays
between the first prescription and the last prescription of
bisphosphonatesforwhichthepatienthasmedicationsupplied.
Secondly, we identified patients who had filled at least six
prescriptions of bisphosphonates.
We defined bisphosphonate non-users as individuals who were
never prescribed bisphosphonates or who had their first
prescription of bisphosphonates after a revision surgery. Oral
bisphosphonate treatment for a short duration has been shown
not to have a biologically plausible effect on bone strength,
basedonclinicaloutcomes.
16Therefore,wealsoclassifiedpartial
usersofbisphosphonatesasnon-users—thatis,individualswith
fewer than six prescriptions and either less than six months of
treatment or a medication possession ratio of less than 0.8.
Covariates
Weconsideredthefollowingpotentialconfoundersforthestudy:
• Age
• Sex
• Body mass index
• Type of joint replaced (hip/knee)
• Year of joint replacement operation
• Recorded diagnosis of osteoarthritis (yes/no)
• Previous fracture before surgery (yes/no)
• Use of calcium and vitamin D supplements (yes/no)
• Useofhormonereplacementtherapyorselectiveoestrogen
receptor modulators (yes/no)
• Oral glucocorticosteroid treatment (yes/no)
• Smoking status and alcohol intake, recorded closest to the
date of primary surgery
• Generalpracticedeprivationscore(asdefinedbytheIndex
of Multiple Deprivation)
• Location of surgery (UK region)
• Comorbid conditions registered by physician: asthma,
malabsorptive syndromes, inflammatory bowel disease,
hypertension, hyperlipidaemia, ischaemic heart disease,
and stroke
• Chronic obstructive pulmonary disease (yes/no)
• Chronic kidney failure (yes/no)
• Neoplasms (yes/no)
• Diabetes (yes/no)
• Use of drugs that might affect fracture risk: proton pump
inhibitors, antiarrhythmics, anticonvulsants,
antidepressants, anti-parkinson drugs, statins, thiazide
diuretics, and anxiolytics
We identified patients with a previous hip fracture by using the
followingREADandOXMIScodes:S302.00,S30y.00,S30..11,
S302400, S30..00, S305.00, S314.00, S31..00, S310100,
S31z.00, 7K1L400, S30y.11, S310.00, 14G7.00, 820 T, 820 B,
8210, and 820A.
Statistical analyses
We used propensity score adjustment to reduce the effects of
confounding by indication and to accurately estimate the effect
ofbisphosphonatesinanon-experimentalobservationalstudy.
17
The propensity score for bisphosphonate use represents the
probabilitythatapatientisprescribedbisphosphonatetreatment,
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RESEARCHand was estimated for the whole study population by
multivariate logistic regression modelling.
18 Bisphosphonate
use was a binary outcome and fractional polynomial regression
modelling was used to account for non-linear effects of age and
body mass index.
Weimputeddataforimportantmissingcovariates(thatis,body
mass index, smoking, and alcohol intake) in the propensity and
survival models, because the cumulative effect of missing data
often excludes a substantial proportion of the original sample,
causingalossofprecisionandpower.Thisbiascanbeovercome
bymultipleimputation,whichavoidstheuncertaintyofmissing
data by creating several plausible imputed datasets and
appropriately combining their results. We used the procedure
for imputation by chained equations in Stata,
19 and included all
predictor variables in the multiple imputation process, together
with the outcome variable and length of follow-up time on the
log scale since this information helps calculate the missing
values of the predictors. The resulting logistic equation for a
propensity score yielded a C statistic of 0.78 (95% confidence
interval 0.77 to 0.79), indicating a good adjustment for
confounding by indication.
Wecalculatedunadjustedratesofimplantrevisionatfiveyears
for bisphosphonate users and non-users. We then tested the
association between bisphosphonate use and implant revision
using survival models adjusted for propensity score. Patients
wholefttheregisteredpracticeordiedwererightcensored.We
first illustrated implant survival using non-parametric
Kaplan-Meier plots, and then used parametric Weibull survival
models to measure the effect of bisphosphonate use on implant
survival both as a hazard function and a time ratio to improve
interpretation.
20Assumptionsunderlyingtheparametricsurvival
modelwereassessedwithlikelihoodratiotests,withnoevidence
seen of non-proportional hazards or times.
We had postulated a priori that an interaction between
bisphosphonateuseandthefollowingvariablesmightbepresent:
sex, history of fracture before surgery, or type of joint replaced
(knee or hip). To test for these variables, we included
multiplicative interaction terms in survival models. However,
in view of the strong protective effect of bisphosphonates on
implant survival, the treated group did not have enough events
to model these interactions.
As a guide to the clinical effect size, we calculated the number
needed to treat to avoid one revision at 15 years of follow-up,
based on the survival probability function and the hazard ratio.
We did all statistical analyses using Stata (version 11.1).
Results
Of 48 453 eligible patients with primary total arthroplasty of
the hip (n=27 039) or knee (n=21 414), we excluded 6458
(13.3%)fromouranalyses.Inall,2081(4.3%)excludedpatients
had a physician diagnosis of rheumatoid arthritis, 609 (1.3%)
underwent arthroplasty at age less than 40 years, and 3768
(7.8%) had a history of hip fracture before primary surgery (fig
1⇓). Accordingly, we included and followed up 41 995
participantswithhip(n=23269)orknee(n=18726)arthroplasty
for a median of 3.5 years (interquartile range 1.6-6.3). Of 1912
(4.6%)patientsclassifiedasbisphosphonateusers,1484(77.6%)
did not have any history of fracture before the primary
arthroplasty and the remaining 428 participants had at least one
fracture before undergoing revision joint arthroplasty.
Themediandurationofbisphosphonatetreatmentandwas3.07
years (interquartile range 1.65-5.20) and the median number of
prescriptions was 19 (11-33). The median time (interquartile
range)fromfirstbisphosphonateprescriptiontoprimarysurgery
was 11.8 months (14.5 months before surgery to 39.5 months
after surgery). Median time from first prescription to revision
surgery was 34.0 months (10.8-55.5 months). Compared with
non-users, bisphosphonate users were significantly older,
thinner, and more likely to be female; they also had more
comorbidities and used more fracture related drugs. We used
these attributes for the propensity adjustment (table 1⇓).
Bisphosphonate users and revision rates
At five years’ follow-up, 522 (1.2%) participants had revision
surgery (304 (1.3%) for hip, 218 (1.2%) for knee). Overall, we
recorded 511 (1.3%) revisions (296 (1.3%) hip, 215 (1.2%)
knee) in bisphosphonate non-users, with a lower rate of 11
(0.6%) in users (eight (0.8%) hip, three (0.3%) knee). For
patients with at least five years of follow-up, bisphosphonate
users had a lower revision rate at five years than non-users
(0.93% (95% confidence interval 0.52% to 1.68%) v 1.96%
(1.80% to 2.14%)).
Table 2⇓ and figure 2⇓ show that bisphosphonate use had a
strongly protective effect on implant survival throughout the
study(adjustedhazardratio0.54(95%confidenceinterval0.29
to 0.99), P=0.047), with a significant increase in median
prosthesis survival (time ratio 1.96 (1.01 to 3.82)). After
stratifying for the type of joint replaced (knee or hip), we found
that the time to revision more than doubled after knee
arthroplasty,withaborderlinesignificance(timeratio2.37(0.94
to 6.01)), and increased by a non-significant 70% after hip
arthroplasty (1.71 (0.74 to 3.94)).
As a sensitivity analysis, we repeated these propensity adjusted
survival models for the 34 336 (81.8%) patients who had a
documented diagnosis of osteoarthritis in their primary care
records.Amongthesepatients,bisphosphonateusehadagreater
protectiveeffectonfailurerisk(adjustedhazardratio0.40(0.17
to 0.93), P=0.034; time ratio 2.69 (1.07 to 6.73)).
Assuming an accumulated incidence of failure of 2% over five
years,weestimatedthatthenumbertotreattoavoidonerevision
was 107 for patients aged more than 40 years undergoing lower
limb arthroplasty for osteoarthritis.
Discussion
We have shown that bisphosphonate use is associated with a
significantly lower rate of revision surgery of up to about 50%
andatwofoldgreatermedianimplantsurvivaltimeafterprimary
totalarthroplastyofthelowerlimbinpatientswithoutaprevious
fracture. The observed effect size was higher for patients who
had a knee arthroplasty than for those who had a hip
arthroplasty, although the statistical power to confirm this
difference was limited. Finally, in patients diagnosed with
osteoarthritisbytheirgeneralpractitioners,bisphosphonateuse
had a greater protective effect, with an almost threefold greater
median prosthesis survival time.
Comparison with other studies
The most common cause of failure of a hip or knee prosthesis
requiring revision is aseptic loosening, which accounted for
around56%and41%ofrevisionsdoneaftertotalarthroplasties
of the hip and knee, respectively, in the UK in 2009.
21 The
mechanism for loosening is thought to be a sustained chronic
inflammatoryresponse,whichrecruitsmacrophages,osteoclasts,
and other cells to accelerate the loss of periprosthetic bone.
These pathways could be prevented by bisphosphonate
treatment.
22
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RESEARCHCurrently published data are conflicting about the protective
effect of bisphosphonates on different surrogates for total hip
or knee arthroplasty failure. Although some authors
13 have not
found any significant effect of oral bisphosphonates, others
9-12
have reported a potential benefit of bisphosphonates, both as
oral or intravenous treatment, on several surrogate markers for
failuresuchasboneintegrationandprosthesismigration.While
the studies showing a beneficial effect have covered oral, local,
and intravenous treatment of bisphosphonates, the intervention
groupintheonlystudyshowingnoeffectonimplantmigration
14
receivedweeklydosesoforalalendronateforsixmonths,which
was the minimum duration of treatment we considered in our
study to define bisphosphonate users. Regarding the effect of
bisphosphonatesonperiprostheticboneloss,arecentlypublished
systematic review
23 and a meta-analysis
24 have also provided
conflicting results.
Ourresultsareconsistentwithmostofthepublishedtrials,since
weshowedasignificantprotectiveeffectoforalbisphosphonates
on implant failure risk after hip or knee arthroplasty, using
revision as the clinical end point. Although we did not have
enough statistical power to show a definitive result, the
protectivebenefitofbisphosphonateuseseemedmosteffective
after five years, when the most common cause of failure is
loosening secondary to osteolysis.
A recent case-control study from the Danish Hip Arthroplasty
Registerreportedanon-significantassociationbetweenthelong
term use of bisphosphonates and a reduced risk of revision, but
an increased risk of revision due to deep infections among
bisphosphonate users.
25 However, unlike our study, the
researchers restricted their sample to patients with either
osteoporosis (as registered in the database) or a previous
osteoporotic fracture, they only examined effects on total hip
arthroplasty, and they did not exclude individuals with
rheumatoidarthritis,whowouldhaveprobablybeenatanraised
risk of loosening due to increased rates of bone turnover and
infection caused by immunosuppression. In our study, we
excluded patients with a previous hip fracture (in whom the
mechanism for revision is likely to lead to complications such
as altered gait and risk of falls
26 and persisting periprosthetic
symptoms) but included individuals with fractures at other
skeletal sites.
Our finding of a stronger protective effect associated with
bisphosphonate use in patients with a confirmed diagnosis of
osteoarthritis could indicate misclassification of participants
withoutacodeforosteoarthritiseventhoughweexcludedthose
with a diagnosis of rheumatoid arthritis or hip fracture.
Furthermore, patients with a primary care diagnosis of
osteoarthritis might also have more severe disease, either
structurally and or symptomatically. Further work should aim
to identify the radiographic grade and patient symptom score
at the time of surgery and the benefit from bisphosphonate use.
We have published a potential role for bisphosphonates in
minimising the increased risk of fractures seen immediately
after a total knee arthroplasty.
27 28 If, in addition to fracture
reduction,bisphosphonateuseleadstoareducedriskofimplant
failure and therefore an extension of implant survival, its use
should be assessed in clinical settings. If these findings are
replicated in other observational cohorts, a randomised clinical
trial is needed to test the efficacy and cost effectiveness of
bisphosphonate use at or before the time of surgery to improve
implant survival and reduce fracture risk.
We estimated that the number of patients needed to treat to
avoidonefailurewas107fororalbisphosphonates.Thisnumber
is about five times that needed to avoid one vertebral fracture
in patients with osteoporosis (range 9-21), and higher than the
number corresponding to the effect of oral bisphosphonates on
hip fracture prevention (91 patients).
29 However, the costs of
revision surgery are higher than either of these two settings; the
estimated average total cost for all types of revision
arthroplasties is about $54 000 (£34 268.40; €40 078.80).
6
Potentialsideeffectsassociatedwithbisphosphonateuseshould
betakenintoaccountbeforeinitiatingtreatmentinthesepatients.
However, the relatively low incidence of side effects (1-0.1/10
000 patient years for treatment for osteonecrosis of the jaw
30 31
and about 5/10 000 patient years for atypical fractures
32) seems
very low when compared with our estimated number needed to
treat. Further work needs to establish whether individuals who
will benefit most from treatment can be identified within the
heterogeneity of patient groups who undergo total joint
arthroplasty, in terms of age, sex, and other established
determinants for poor skeletal status.
Strengths and weaknesses of the study
This study’s main strengths were the long period of follow-up
and the generalisability of the General Practice Research
Database, which represents the vast majority of patients
undergoing total joint arthroplasty. Population based cohorts
provide data for a wide range of subjects, including both sexes,
older patients, and individuals with comorbid conditions. In
addition, data from the General Practice Research Database
accurately reflect primary care in the UK, because they are
collected from a representative sample of general practices.
Hence, the observed protective effect of bisphosphonate use on
implant survival could be assumed to be valid for the wider
population of patients undergoing a total hip or knee
replacement.
A potential limitation was the completeness of the coding for
revision surgery and of important potential confounding
variables.Nevertheless,theGeneralPracticeResearchDatabase
has been widely used for epidemiological research, with high
validity and completeness for prescription data and discrete
outcomes such as fracture and surgery.
In the absence of information indicating the side of primary or
revision surgery in patients with bilateral replacements, some
revisionscouldhavebeencontralateraltotheprimaryoperation.
We propose that this misclassification would have little effect
onourresults;ourobservedrevisionrate(about2%foramedian
3.5 years of follow-up) was similar to that reported by the
National Joint Registry (2.9% for and 3.6% for total hip and
knee arthroplasty, respectively, at five years of follow-up).
2
Furthermore, any misclassification would probably be random
in the groups of bisphosphonate users and non-users, and
therefore would tend to bias our results towards the null
hypothesis.
The design of this study was observational, and considerable
controversy exists on whether this type of study can provide
reliable information on causality and, especially, on the
effectivenessofdrugs.
33Nevertheless,wehaveusedpropensity
score adjustment as a method to control for confounding by
indication, which is currently recognised as the best analytical
approach to reduce such confounding.
17 Furthermore, findings
from observational studies using electronic medical records
from primary care databases (such as the General Practice
Research Database) have been compared with findings from
randomised control trials, with promising results if appropriate
methods (such as propensity score adjustment) are used to
reduce confounding.
34
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RESEARCHUnsolvedissueswereresidualconfounding(duetounobserved
variables such as bone mineral density, ethnic origin, design of
implant, or type of fixation) and the absence of a non-active
comparator compound to take into account the placebo effect.
Furthermore, we could not assess the effect of other
antiresorptive drugs on implant survival, because only 13
patients could be defined as calcitonin users and one patient as
a strontium ranelate user. We also did not identify any users of
either parathormone or bisphosphonate preparations that
included vitamin D, because the last patient was followed up
until the end of 2006, when these drugs were not available in
the UK.
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RESEARCHWhat is already known on this topic
Although bisphosphonates have theoretical benefits on implant survival, direct evidence for effects on clinical outcomes is scarce
What this study adds
In an observational cohort of patients undergoing lower limb arthroplasty, bisphosphonate use was related to an almost twofold increase
in implant survival time. These findings need confirmation in experimental studies
Tables
Table 1 | Baseline characteristics. Values are numbers (percentages) unless stated otherwise
Bisphosphonate use
Total population (n=41 995) P value of difference No (n=40 083) Yes (n=1912)
<0.001 69.80 (9.70) 73.83 (8.15) 69.98 (9.67) Mean (SD) age (years)
<0.001 23 104 (57.6) 1629 (85.2) 24 733 (58.9) Sex (female)
<0.001 28.16 (4.88) 26.64 (4.86) 28.09 (4.88) Body mass index (kg/m
2)*
Smoking status*:
<0.001 4479 (11.6) 161 (8.6) 4640 (11.1) Yes
21 931 (56.8) 1100 (58.4) 23 031 (54.8) No
12 211 (31.6) 622 (33.0) 12 833 (30.6) Former smoker
Alcohol drinking status*:
<0.001 28 188 (79.3) 1256 (73.5) 29 444 (70.1) Yes
5052 (14.2) 290 (17.0) 5342 (12.7) No
2306 (6.5) 163 (9.5) 2469 (5.9) Former drinker
0.73 22 217 (55.4) 1052 (55.0) 23 269 (55.4) Joint replaced (hip)
0.058 32 804 (81.8) 1532 (80.1) 34 336 (81.8) Osteoarthritis of the knee or hip
<0.001 4545 (11.3) 156 (8.2) 4701 (11.2) Diabetes
0.041 4057 (10.1) 166 (8.7) 4223 (10.1) Cardiovascular disease
Deprivation score (general practice)*:
0.023 9242 (23.2) 444 (23.4) 9686 (23.1) 0
6764 (17.0) 305 (16.1) 7069 (16.8) 1
8363 (21.0) 452 (23.9) 8815 (21.0) 2
8313 (20.9) 358 (18.9) 8671 (20.7) 3
7140 (17.9) 336 (17.7) 7476 (17.8) 4
No of comorbid conditions†:
<0.001 15 621 (39.0) 536 (28.0) 16 157 (38.5) 0
14 903 (37.2) 744 (38.9) 15 647 (37.3) 1
6742 (16.8) 427 (22.3) 7169 (17.1) 2
2153 (5.4) 154 (8.1) 2307 (5.5) 3
664 (1.7) 51 (2.7) 715 (1.7) ≥4
Time to implant failure (years):
511 (1.3) 11 (0.6) 522 (1.2) 0 to 5
736 (1.8) 12 (0.6) 748 (1.8) 0 to 15
<0.001 3.57 (1.63-6.41) 3.21 (1.56-5.19) 3.54 (1.63-6.33) Median (IQR) follow-up time before
failure
<0.001 5256 (13.1) 428 (22.4) 5684 (13.5) Fracture before primary surgery
Use of other drugs:
0.003 5618 (14.0) 315 (16.5) 5933 (14.1) HRT-SERM
<0.001 457 (1.1) 96 (5.0) 553 (1.3) Calcium-vitamin D supplements
0.11 109 (0.3) 9 (0.5) 118 (0.3) Oral corticosteroids
<0.001 8893 (22.2) 502 (26.3) 9395 (22.4) Other drugs associated with
increased fracture risk‡
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RESEARCHTable 1 (continued)
Bisphosphonate use
Total population (n=41 995) P value of difference No (n=40 083) Yes (n=1912)
IQR=interquartile range. HRT-SERM=hormone replacement therapy-selective oestrogen receptor modulator. χ
2 test and t test used to compare categorical and
continuous variables, respectively.
*Missing data for body mass index (n=5122), smoking (n=1491), alcohol drinking status (n=4740), and deprivation score (n=278).
†Any of the following: asthma, malabsorption syndromes, inflammatory bowel disease, hypertension, hyperlipidaemia, ischaemic heart disease, cerebrovascular
disease, chronic obstructive pulmonary disease, chronic renal failure, and cancer.
‡Any of the following: anti-arrhythmic drugs, anticonvulsants, or tricyclic antidepressants.
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RESEARCHTable 2 | Parametric Weibull model assessment of the effect of bisphosphonate use on prosthesis survival, up to 15 years after surgery
Propensity adjusted models Unadjusted models
Study group
P value* Time ratio (95% CI) for
implant survival
Hazard ratio (95% CI) for
implant failure
P value* Time ratio (95% CI) for
implant survival
Hazard ratio (95% CI) for
implant failure
0.047 1.96 (1.01 to 3.82) 0.54 (0.29 to 0.99) 0.004 2.54 (1.34 to 4.83) 0.41 (0.22 to 0.76) Total population (n=41 995)
0.034 2.69 (1.07 to 6.73) 0.40 (0.17 to 0.93) 0.005 3.47 (1.44 to 8.37) 0.30 (0.13 to 0.70) Population diagnosed with
osteoarthritis (n=34 336)
0.068 2.37 (0.94 to 6.01) 0.40 (0.15 to 1.07) 0.027 2.79 (1.12 to 6.91) 0.33 (0.12 to 0.88) Population undergoing knee
arthroplasty (n=18 726)
0.20 1.71 (0.74 to 3.94) 0.64 (0.32 to 1.28) 0.033 2.36 (1.07 to 5.21) 0.47 (0.24 to 0.94) Population undergoing hip
arthroplasty (n=23 269)
P values apply to both time ratios and hazard ratios.
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RESEARCHFigures
Fig 1 Population flowchart
Fig 2 Kaplan-Meier and Weibull model estimates for revision events after primary total arthroplasty of the hip, knee, and
joint
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